Table 2.
Anti-3-[18F]FACBC vs 111In-capromab pendetide diagnostic performance in prostate/bed and extraprostatic sites
| Anti-3-[18F]FACBC | 111In-Capromab Pendetide | p Value | |
|---|---|---|---|
| Prostate/bed (91 pts): | |||
| No. true pos | 55 | 41 | – |
| No. true neg | 12 | 17 | – |
| No. false-pos | 18 | 13 | – |
| No. false-neg | 6 | 20 | – |
| % Sensitivity (95% CI) | 90.2 (79.8, 96.3) | 67.2 (54.0, 78.7) | 0.002 |
| % Specificity (95% CI) | 40.0 (22.7, 59.4) | 56.7 (37.4, 74.5) | 0.182 |
| % Accuracy (95% CI) | 73.6 (63.3, 82.3) | 63.7 (53.0, 73.6) | <0.001 |
| % PPV (95% CI) | 75.3 (63.9, 84.7) | 75.9 (62.4, 86.5) | 0.530 |
| % NPV (95% CI) | 66.7 (41.0, 86.7) | 45.9 (29.5, 63.1) | 0.074 |
| Extraprostatic (70 pts): | |||
| No. true pos | 22 | 4 | – |
| No. true neg | 29 | 26 | – |
| No. false-pos | 1 | 4 | – |
| No. false-neg | 18 | 36 | – |
| % Sensitivity (95% CI) | 55.0 (38.5, 70.7) | 10.0 (2.8, 23.7) | <0.001 |
| % Specificity (95% CI) | 96.7 (82.8, 99.9) | 86.7 (69.3, 96.2) | 0.248 |
| % Accuracy (95% CI) | 72.9 (60.9, 82.8) | 42.9 (31.1, 55.3) | 0.003 |
| % PPV (95% CI) | 95.7 (78.1, 99.9) | 50.0 (15.7, 84.3) | 0.001 |
| % NPV (95% CI) | 61.7 (46.4, 75.5) | 41.9 (29.5, 55.2) | 0.021 |